3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Neoplasms by Site
2
Neoplasms
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Radiosurgery
22
Nivolumab
21
Ipilimumab
19
pembrolizumab
15
Temozolomide
11
dabrafenib
10
binimetinib
10
encorafenib
8
Cyclophosphamide
8
trametinib
7
Magnetic Resonance Spectroscopy
7
Bevacizumab
6
fludarabine
5
cobimetinib
5
Specimen Handling
5
CTLA-4 Antigen
5
fludarabine phosphate
3
aldesleukin
3
Vemurafenib
3
Thalidomide
3
Paclitaxel
3
Oxaliplatin
3
Interleukin-2
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ulixertinib
2
tovorafenib
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
alectinib
×
CNS
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts